Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer ...

Get a high-probability setup with clear entry and exit points right here. Eli Lilly And Co LLY, on Sunday, announced positive Phase 2 results for lepodisiran, an investigational small interfering ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will prevent heart attacks and strokes. By Gina Kolata As many as one in five ...

Eli Roth‘s The Horror Section has acquired “Jimmy and Stiggs,” marking the horror company’s first major deal since launching earlier this month, Variety can exclusively report. Directed ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...

“Semaglutide generics will be priced almost 95% lower than [Eli Lilly'] current price,” said Vishal Manchanda, senior vice-president, institutional research at Systematix Group. With the drop ...

By Borys Kit Senior Film Writer There will be blood. And probably lots of it. Filmmaker Eli Roth has launched The Horror Section, a new, all-encompassing horror media company that aims not just to ...

On Tuesday, a group of senators sent letters to five telehealth companies that offer care through direct-to-consumer portals from pharmaceutical manufacturers Pfizer and Eli Lilly, interrogating ...